Skip to main content
Nancy Bartlett, MD, Oncology, Saint Louis, MO

NancyLeeBartlettMD

Oncology Saint Louis, MO

Hematologic Oncology

Professor, Internal Medicine, Washington University School of Medicine

Dr. Bartlett is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bartlett's full profile

Already have an account?

  • Office

    4921 Parkview Pl
    # Dv
    Saint Louis, MO 63110
    Phone+1 800-647-2098
    Fax+1 314-362-3192

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1990 - 1993
  • University of California (San Francisco)
    University of California (San Francisco)Internship, Internal Medicine, 1986 - 1987
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 1986

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1988 - Present
  • MO State Medical License
    MO State Medical License 1993 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma  
    Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
  • Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study  
    Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica
  • Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma  
    Ian W Flinn, Nancy L Bartlett, The New England Journal of Medicine
  • Join now to see all

Abstracts/Posters

  • The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
    Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
    Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
    Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
  • Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • At ASH, Regeneron Plays Catch-up with Its Next Cancer Drugs
    At ASH, Regeneron Plays Catch-up with Its Next Cancer DrugsDecember 12th, 2022
  • Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
    Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular LymphomaJuly 12th, 2022
  • Pulling Back the Curtain: Bill Blum, MD, and Kristie Blum, MD
    Pulling Back the Curtain: Bill Blum, MD, and Kristie Blum, MDMarch 1st, 2021
  • Join now to see all

Grant Support

  • Wumc Cancer And Leukemia Group BNational Cancer Institute2009–2012
  • Data And Safety MonitoringNational Cancer Institute2010–2011
  • Wumc-Cancer And Leukemia Group BNational Cancer Institute2003–2008
  • Quality Assurance And Safety MonitoringNational Cancer Institute2004
  • 24hr Infusion Of Hmr1275 In Fludarabine--B Cell LeukemiaNational Center For Research Resources2000–2002
  • Wusm Cancer And Leukemia Group BNational Cancer Institute1998–2002
  • Coadmin Rising Oral Gg918 Dose Levels (GH120918) W/ Doxorubicin In Cancer PTSNational Center For Research Resources1998–1999

Professional Memberships